1-Phenyl-N-methylcyclobutylamin | 30839-61-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-Phenyl-N-methylcyclobutylamin
• 英文别名: N-Methyl-1-phenylcyclobutanamine；N-methyl-1-phenylcyclobutan-1-amine
• CAS: 30839-61-3
• 化学式: C₁₁H₁₅N
• mdl: MFCD20547457
• 分子量: 161.247
• InChiKey: IGVLHXBWKQCGET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS<br/>[FR] COMPOSÉS D'URÉE ACYCLIQUES SERVANT DE MODULATEURS DE LA GAMMA-SÉCRÉTASE
  申请人：AMGEN INC

  公开号：WO2009137404A1

  公开（公告）日：2009-11-12

  The present invention provides compounds Formula (I) that are gamma secretase modulators and are therefore useful for the treatment of diseases treatable by modulation of gamma secretase such as Alzheimer's disease. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明提供了化合物Formula (I)，它们是γ-分泌酶调节剂，因此可用于治疗通过调节γ-分泌酶可治疗的疾病，如阿尔茨海默病。还提供了含有这些化合物的药物组合物以及制备这些化合物的方法。
• PYRIMIDINE COMPOUND
  申请人：Matsushima Yuji

  公开号：US20110053912A1

  公开（公告）日：2011-03-03

  A novel and excellent method for preventing and/or treating diseases related to a cannabinoid type 2 receptor, based on an agonistic action on a cannabinoid type 2 receptor. It was found that a hetero ring derivative mainly having two substituents, for example, a pyrimidine-5-carboxamide derivative having a substituent amino group at the 2-position, exhibits a potent agonistic action on a cannabinoid type 2 receptor, and can be an agent for preventing and/or treating diseases related to a cannabinoid type 2 receptor such as inflammatory diseases, pain, and the like.

  一种预防和/或治疗与大麻素2型受体相关疾病的新颖优秀方法，基于对大麻素2型受体的激动作用。发现一种异核环衍生物主要具有两个取代基，例如，在2-位置具有取代基氨基的嘧啶-5-羧酰胺衍生物，表现出对大麻素2型受体的强效激动作用，可以成为预防和/或治疗与大麻素2型受体相关疾病，如炎症性疾病、疼痛等的药物。
• [EN] CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS<br/>[FR] PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZÈNESULFONAMIDES CYCLIQUES, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
  申请人：SANOFI AVENTIS

  公开号：WO2009080223A1

  公开（公告）日：2009-07-02

  The invention relates to cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What is described are compounds of the Formula (I), in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  该发明涉及环状N-[1,3,4]-噻二唑-2-基苯磺酰胺及其生理上可接受的盐和生理功能衍生物，显示出PPARδ或PPARδ和PPARγ激动剂活性。所描述的是Formula (I)的化合物，其中基团如所定义，并且它们的生理上可接受的盐及其制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍，以及胰岛素抵抗相关的疾病，以及中枢和外周神经系统的脱髓鞘化和其他神经退行性疾病。
• CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE THEREOF
  申请人：SCHOENAFINGER Karl

  公开号：US20080280959A1

  公开（公告）日：2008-11-13

  The present invention comprises cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, their functional derivatives as well as their physiologically acceptable salts and pharmaceutical compositions thereof that exhibit peroxisome proliferator activated receptor (PPAR) PPARdelta and PPARgamma agonist activity. The structure of the compounds of the invention are defined by Formula I below, wherein the various R1-R9 substituents are defined herein. Processes for the compounds preparation are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明包括环状N-[1,3,4]-噻二唑-2-基苯磺酰胺，它们的功能衍生物以及其生理上可接受的盐和药物组成物，具有过氧化物酶体增殖物激活受体（PPAR）PPARδ和PPARγ激动剂活性。该发明化合物的结构由下式I定义，其中各种R1-R9取代基在此定义。本发明还揭示了化合物的制备过程。该化合物适用于治疗与脂肪酸代谢和葡萄糖利用障碍有关的疾病，涉及胰岛素抵抗以及中枢和周围神经系统的脱髓鞘和其他神经退行性疾病。
• Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
  申请人：SCHOENAFINGER Karl

  公开号：US20110224263A1

  公开（公告）日：2011-09-15

  The invention relates to cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及环状N-[1,3,4]-噻二唑-2-基苯磺酰胺及其生理上可接受的盐和生理功能衍生物，表现出PPARdelta或PPARdelta和PPARgamma激动剂活性。所描述的是式I的化合物，其中基团的定义如上所述，以及它们的生理上可接受的盐和制备过程。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用紊乱以及胰岛素抵抗涉及的疾病，以及中枢和外周神经系统的脱髓鞘和其他神经退行性疾病。